Kornimate/medical-research-clean huggingface dataset:
patient experience of interventional pain management. qualitative study

Conditions: Chronic Pain

Summary: there are quite a few qualitative studies done to find out patients experience of chronic pain. there are no studies on what the patients feel and what thoughts and feelings arise in the patients that are exposed to interventional pain management. this study aims to illuminate how it is to live through an interventional pain management program.

a qualitative interview is performed with patients that have passed through an interventional pain management program. the transcribed interviews are analyzed with qualitative content analysis according to graneheim and lundman in order to illuminate the experience, feelings and thoughts arisen among the patients.

Eligibility criteria:
inclusion criteria: patients passed through an interventional pain management program exclusion criteria: purposeful sampling will be applied
incidence of symptomatic and asymptomatic bacteriuria after urodynamic study in women

Conditions: Female Stress Incontinence

Summary: urodynamic study (uds) represents a series of agreed-upon clinical tests and is used to evaluate the functional status of the lower urinary tract, providing a pathophysiological basis for urinary symptoms. urodynamic study involves catheterization of the lower urinary tract. the prevalence of urinary tract infection after uds ranges from 1,5% to 30 %. studies of prophylactic antibiotics for udss have offered data of contradictory and limited predictive values. some investigators concluded that prophylactic antibiotics were valuable and others have not. the objective of this study is to evaluate the efficacy of antibiotic prophylaxis before uds in women, using different antibiotic regimens.

this study is randomized, double blind study was carried out in the department of gynecology at sao paulo federal university from january 2009 to december 2012. the patients were randomized in four groups: group a received 500mg of levofloxacin, group b received placebo, group c received 80mg trimethoprim and 400mg sulfamethoxazole (smz-tmp) and group d received 100mg of nitrofurantoin. the tablets were administered 30 minutes before de uds. all patients were instructed to collect midstream urine sample to the microbiology laboratory 14 days after the uds. significant bacteriuria was considered when \>1.000.000 organisms/ml of a single species was isolated. all data were entered into statistical package for social sciences (spss) 16.0 for statistical analysis and graphic representation. likelihood -ratio test and fisher's exact test were used to compare the prevalence of significant bacteriuria after uds in the different groups and student's t-test and anova test were used to compare continuous variables. to compare the groups regarding the bmi variable and parity, the model analysis of variance (anova) was used, or if necessary, the nonparametric kruskal-wallis test and to compare the groups in relation to menopause variable, we used the chi-square test. a significance level of 0.05 was established for statistical analysis.

Eligibility criteria:
* inclusion criteria: women with 20 to 85 years old, clinical diagnosis of urinary incontinence with indication for urodynamic study, absence of genital prolapse or prolapse peak effort that does not exceed the hymen, absence of urinary tract infection * exclusion criteria: patients with diabetes mellitus, history of recurrence urinary tract infection, with genital prolapse that exceed de hymen, pregnant, kidney stone, allergy to antibiotics, use of urethral catheters delay

Keywords: urodynamics cystitis prophylactic antibiotics bacteriuria
safety study of mva smallpox vaccine in subjects with a history of atopic dermatitis (ad)

Conditions: Smallpox; Atopic Dermatitis

Summary: purpose of this study is to assess the safety and immunogenicity of two mva smallpox vaccine injections in healthy adults that are 18-35 years of age with a history of mild to moderate atopic dermatitis.

this is a randomized, double-blind, placebo-controlled study. subjects will be randomized to receive investigational vaccine or placebo at a ratio of 3.5:1, mva3000 to placebo. all subjects will undergo a screening period, a treatment/observation period during which all subjects will receive injections on study day 0 and study day 28 of investigational vaccine or placebo. the clinical observation period will be completed at day 56. a visit will occur at approximately 3 months after the second study injection (study day 118) for additional blood collection and a review of the subject's health status. follow-up will be obtained via telephone contacts approximately 6 months after the end of the second injection during the treatment/observation period.

Eligibility criteria:
inclusion criteria: * adults at least 18 years old and who were born after 1971 with no previous history of smallpox vaccination * subjects must be in good general health female subjects must not be pregnant or lactating and must agree to practice birth control during the course of the study * subjects must have a diagnosis of ad by an experienced clinician that includes a history of both major and minor diagnostic criteria * at the time of screening, the subject must have "mild to moderate" ad. exclusion criteria: * history or evidence of prior exposure to a vaccinia or mva- containing product * known or suspected history of immunodeficiency other than ad * known or suspected impairment of major organ function * known history or diagnosis of cardiac disease or cerebrovascular disease * presence of acute, chronic, or active exfoliative skin conditions other than ad, open wounds, or burns. * dementia or history of seizures * known allergies to mva or any known components of the vaccine * transfusion of blood, organ transplantation, or treatment with any blood product * morbid obesity, or a bmi less than or equal to 18.5 * history of or current drug or alcohol abuse (except nicotine) within the past 6 months or any history of iv drug use * history of major psychiatric illness except major depression not requiring medical therapy. * subjects who have participated in another investigational drug or vaccine trial within 30 days of study day 0
predictors of anterior patellofemoral pain after anterior cruciate ligament reconstruction

Conditions: Anterior Cruciate Ligament Reconstruction

Summary: observational, ambispective, longitudinal, monocentric, open cohort study of a population of adult patients operated on for acl reconstruction and receiving postoperative follow-up.

on a large population of adult patients operated on for anterior cruciate ligament reconstruction and followed over a 12-month period under standard medical practice conditions. primary objective: to investigate, six months after surgery, the presence of patellofemoral pain and to evaluate the factors predictive of the occurrence of such pain. secondary objectives: * evaluate the incidence of patellofemoral pain at 12 months. * compare the functional status of patients with and without patellofemoral pain at 6 and 12 months.

Eligibility criteria:
inclusion criteria: * patient aged 18 or over * patient who has been informed of the research and does not object to data collection * patient who has undergone or is about to undergo acl ligamentoplasty surgery * regularly followed-up patient for whom the data required by the protocol will be available in the medical record history of contralateral acl rupture exclusion criteria: * history of associated fracture * history of multi-ligament reconstruction
dynamic contrast enhanced ultrasound for predict and assess rectal cancer response after neo-adjuvant chemoradiation - rect

Conditions: Rectal Cancer

Summary: in recent years the concept of organ sparing treatment in rectal cancer was introduced for selected good responders after neo-adjuvant treatment. in these patients replacement of the standard of care total mesorectal excision (tme) by transanal endoscopic microsurgery (tem) or omission of surgery after chemoradiation (crt) was proposed. before organ sparing treatments could be applied in clinical practice a reliable patient selection procedure has to be available as only good treatment responders after neo-adjuvant therapy are candidates for such adapted therapy. different imaging modalities have been studied for their ability to distinguish good treatment responders from others. examples of such imaging modalities with some promising results regarding response assessment are fludeoxyglucosepositron emission tomography (fdg-pet), t2-weighted magnetic resonance imaging (t2w-mri), dynamic contrast enhanced magnetic resonance imaging and diffusion weighted mr imaging (dw-mri). besides these modalities dynamic contrast enhanced ultrasound (d-ceus) is a new modality used for tissue characterization and therapy response assessment in several tumor locations, like liver tumors and breast cancer. d-ceus reflect tissue vascular perfusion. for rectal cancer, the value of d-ceus for pathological response prediction and assessment has never been assessed. therefore, in this study we assessed d-ceus to predict and assess pathological response in rectal cancer after neo-adjuvant crt.


Eligibility criteria:
inclusion criteria: * histologically confirmed rectal carcinoma * stade ≥t2 and tumor size ≥3cm * no detectable metastases * patient ≥ 18 years * patient information and written informed consent form signed * patient who can receive radiotherapy and chemotherapy * negative pregnancy test in women of childbearing potential * patient covered by a social security system exclusion criteria: * indication for immediate surgery * primary tumor not measured at the mri before inclusion * previous pelvic radiotherapy * contraindication to sonovue or mri

Keywords: ceus perfusion rectal cancer tumor perfusion radiochemotherapy
toleromune ragweed follow up study

Conditions: Ragweed Allergy; Rhinoconjunctivitis

Summary: ragweed is the primary cause of autumn allergies. the ragweed season begins in mid-august. in the third national health and nutrition examination surveys54.3% of the population had positive test responses to one or more allergens, with the prevalence for short ragweed being 26.2% the purpose of this observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to ragweed allergen in the eec among subjects who completed all dosing visits and the post treatment challenge (ptc) visit in study tr002 approximately one year after the start of treatment.

subjects who were randomised in study tr002 and who completed all dosing visits and the ptc will be invited to attend the screening visit for tr002b. subjects will attend the eec for 4 visits on successive days. following the final eec visit a follow-up visit will be performed 3-10 days later.

Eligibility criteria:
inclusion criteria * previously randomised into study tr002 and completed all treatment visits and the ptc. exclusion criteria * history of asthma (a diagnosis of asthma in childhood may be allowed). * subjects with an fev1 \<70% of predicted. * subjects being treated with beta-blockers. * developed a significant disease, disorder or inability to communicate, since completing study tr002 which, in the opinion of the sponsor's medical representative, may either put the subject at risk because of participation in the study, or influence the results of the study, or the subject's ability to participate in the study.

Keywords: ragweed allergy toleromune ragweed immunotherapy
study on the correlation between neurotrophic factors and the condition of stroke patients

Conditions: Stroke

Summary: stroke is currently the most common disabling disease, which often leads to impairment of sensory, motor, speech and psychological functions, resulting in a reduced quality of life for patients. therefore, post-stroke functional rehabilitation, especially the rehabilitation of physical function and psychological condition, is particularly important for patients to rejoin society. acupuncture can promote the functional recovery of patients and facilitate the rehabilitation of limb function, thus improving the quality of survival of post-stroke patients. neurotrophic factors are diverse, most of which are mainly derived from neuronal cells in the central nervous system and are involved in a variety of neurological functions such as cell growth, differentiation and plasticity, thus promoting recovery of multiple functions after stroke. many studies have found that different interventions affect the prognosis of stroke patients differently, e.g., long-term acupuncture increases serum levels of brain-derived neurotrophic factor in stroke patients and also has better outcomes than controls in post-stroke neurological recovery and the development of post-stroke psychiatric disorders. this study investigated the effects of different therapeutic measures on patients' functional recovery and neurotrophic factors by setting up a controlled and blinded trial design, which could not only provide clinical evidence for the effectiveness of relevant therapeutic measures, but also verify the clinical value of certain neurotrophic factors (e.g., predicting outcome, assessing condition, and preventing adverse events).


Eligibility criteria:
inclusion criteria: * symptom recognition to admission ≤ 72 hours * clear imaging evidence * diagnosis of spontaneous cerebral hemorrhage by an immobilized physician according to relevant guidelines; pre-onset mrs score ≤ 1 exclusion criteria: * this onset was caused by traumatic and violent factors * history of previous intracranial surgery * previous cerebrovascular accident * previous speech disorders and limb movement disorders * participation in other trials in the last three months.
circumflex nerve blocks versus posterior cord nerve blocks in shoulder arthroscopy

Conditions: Postoperative Pain

Summary: shoulder arthroscopy is associated with severe postoperative pain. traditionally, the interscalene approach to the brachial plexus has been employed to manage postoperative pain following shoulder surgery.to provide more complete shoulder joint analgesia, suprascabular nerve block (ssnb) was combined with block of the circumflex nerve which comes from the posterior cord of the brachial plexus that usually gives also upper subscapular, thoracodorsal, lower subscapular and radial nerves.

aim of the work is to compare postoperative analgesic effect of ultrasound guided combined suprascapular and circumflex nerve blocks versus suprascapular nerve and posterior cord blocks at infraclavicular level . thirty four patients aged from 18-70 years old, with asa physical status i-ii-iii and scheduled for shoulder surgeries will be included in the study. patients will be randomly allocated using computer-generated table into one of two groups: * group circumflex → will undergo ultrasound guided ssn+circumflex. * group posterior cord → will undergo ultrasound guided ssn+posterior cord.

Eligibility criteria:
inclusion criteria: * asa i-ii.-iii * undergoing shoulder arthroscopy. exclusion criteria: * patient refusal * known allergy to local anesthetics * bleeding disorders * inability to provide informed consent
paradoxical excitement response during sedation between dexmedetomidine and propofol in hazardous alcohol drinker

Conditions: Anesthesia, Spinal; Sedation, Conscious; Dexmedetomidine; Alcohol Drinking; Anesthesia, Epidural; Propofol

Summary: 1. adequate sedation with classical sedative agents, propofol 2. sedation with propofol may induce paradoxical excitement response in heavy alcohol drinkers 3. dexmedetomidine, α2 receptor agonist, may provide adequate sedation in heavy alcohol drinkers

1. adequate sedation during surgery provide anxiolysis and comfort to patient. insufficient sedation can't provide comfort to patient during surgery, otherwise excessive sedation can cause variable complications like respiratory depression or delayed awakening. 2. dexmedetomidine is a centrally acting α2 receptor agonist that is increasingly being used as a sedative for mac and intensive care with mechanical ventilated patients because of its analgesic properties, "cooperative sedation," and lack of respiratory depression. 3. because of the different site of action between dexmedetomidine and propofol, we assumed that paradoxical excitement responses which appeared in heavy alcohol drinkers in midazolam or propofol-induced sedation might be less observed in dexmedetomidine-induced sedation.

Eligibility criteria:
inclusion criteria: * 19\~65 yr-old patients who is scheduled to undergo knee surgery with regional anesthesia exclusion criteria: * history of taking anxiolytics, hypnotics, antiepileptic drugs * abnormal liver function test (eg: liver cirrhosis, elevated liver enzymes) * history of allergic reaction with dexmedetomidine or propofol * contraindication with regional anesthesia * american society of anesthesiologist physical status iii or iv

Keywords: dexmedetomidine sedation paradoxical excitement response alcohol drinkers
sirolimus with tacrolimus for graft-vs-host disease prophylaxis after related stem cell transplantation

Conditions: Hematologic Malignancies; Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma; Hodgkin's Disease

Summary: the purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (gvhd) in patients following stem cell transplant from a related donor.

* therapy to prevent gvhd will consist of an infusion of tacrolimus intravenously and sirolimus orally once per day starting 3 days before stem cell infusion. this will take place in the hospital where the patient will remain for the duration of the transplant. * sirolimus will continue for 9 weeks at at stable dose, then will be tapered by 1/3 on week 9 and 1/3 on week 17. it will be stopped on week 26 if there is no significant evidence of gvhd. these dose modifications will occur at home and patients will be seen weekly for the first 2 months after discharge. * if gvhd is present, the tapering schedule wil be slower and based upon the patient's clinical condition. * tacrolimus will be given orally once the patient is discharged from the hospital and will be tapered at the same schedule as sirolimus. blood levels of both tacrolimus and sirolimus will be monitored and the dose adjusted accordingly. * during the year following stem cell transplant, blood work will be performed to evaluate the immune system and gvhd.

Eligibility criteria:
inclusion criteria: * patients with hematologic malignancies who will undergo allogeneic hsct from matched family-members. * age greater than 18 * ecog performance status 0-2 * total bilirubin \< 2.0 mg/dl * ast \< 90 iu * serum creatinine \< 2.0 mg/dl exclusion criteria: * active, uncontrolled infection * ejection fraction \< 45% by echocardiogram or muga scan * forced vital capacity \< 60% * uncontrolled hypertension * second transplantation * evidence of hiv infection * cholesterol \> 300 mg/dl * relapsed aggressive burkitt's or burkitt's-like lymphoma

Keywords: graft versus host disease gvhd stem cell transplantation sirolimus tacrolimus
diabetic macular edema: relevance of staging progression on therapeutic outcome

Conditions: Diabetic Macular Edema

Summary: retrospective multi-center observational study on functional and morphological outcome of initial therapy for dme according to esaso morphologic classification.

the esaso morphologic classification of diabetic macular edema defines four stages of progression of the disease: early, advanced, chronic and atrophic maculopathy. this grading is generated by the analysis of seven biomarkers that fully describe the level of retinal damage. aim of this classification is to be a valid method for a comprehensive description of dme in scientific studies or clinical practice. given the recent publication of esaso classification, there aren't observations on the real relevance of grading dme on therapeutic outcome. this retrospective study wants to give a preliminary answer to this important issue. as a corollary outcome, this study will also evaluate the concordance of grading among participants.

Eligibility criteria:
inclusion criteria. eligible eyes at the retrospective review 1. any stage of dme treated with a loading dose of 3 anti-vegf (any type) or 1 iv dexamethasone (step 1). 2. oct scans and retinal maps (radial/raster lines) at baseline (max 1 month before injection) and at one month (max 6 weeks) after the third anti-vegf or at 3 months (max 16 weeks) after iv steroid injection (step 2). 3. va at the time of both oct examinations. exclusion criteria: 1. past ocular surgery of any kind (except for cataract surgery) or ocular pathologies other than diabetic retinopathy. 2. macular edema considered to be due to a cause other than diabetic macular edema. 3. oct examination suggesting that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema. in the case of erm, an oct scan must be sent to the coordinating center for approval. 4. any ocular pathology or ocular condition other than diabetes that in the opinion of the investigator might affect macular edema. 5. history of any therapy (anti-vegf treatment, focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids) for dme or diabetic retinopathy in the past 8 months. 6. history of yag capsulotomy performed within two months before enrollment.

Keywords: diabetic macular edema esaso classification therapy